Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 6/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744121 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL3503521 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL3660521 | 0.81 | — | — | |
| SCHEMBL173508 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL6848102 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1 | |
| Tetraxetan SCHEMBL2635294 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL321989 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1 | |
| Tetraxetan SCHEMBL18018 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1 | |
| Tetraxetan SCHEMBL2017956 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9S1PR1 | |
| SCHEMBL1053015 | 0.80 | HSD17B10 (0.54) | HSD17B10SLC6A9S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236607-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2025-07-24 | — | — | US | disclosed |
| EP-4499148-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | Ohio State Innovation Foundation (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023192534-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2020081450-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236607-A1 | CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF | CDK9, CDK19, CDKL2 | HSD17B10 3340/4885BCHE 3689/4885SLC6A9 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.